Pharmacodynamic modeling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis

Clinical Infectious Diseases

Volumn 61, Issue 1, 2015, Pages 1-8

  Sloan, Derek J ^a,b,c   Mwandumba, Henry C ^a   Garton, Natalie J ^d   Khoo, Saye H ^e   Butterworth, Anthony E ^a,e   Allain, Theresa J ^a   Heyderman, Robert S ^a   Corbett, Elizabeth L ^a,e   Barer, Mike R ^d   Davies, Geraint R ^a,e  

^a UNIVERSITY OF MALAWI   (Malawi)

^b LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

clinical trials; lipid bodies; persistence; sterilizing activity; tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN; LIPID; FAT DROPLET;

ADULT; ARTICLE; BACTERIAL GROWTH; ELIMINATION RATE CONSTANT; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; SPUTUM ANALYSIS; SPUTUM CULTURE; SPUTUM CYTODIAGNOSIS; SPUTUM SMEAR; TREATMENT OUTCOME; ADOLESCENT; AGED; BACTERIAL COUNT; CYTOLOGY; DRUG MONITORING; ISOLATION AND PURIFICATION; MALAWI; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; PROSPECTIVE STUDY; SPUTUM; THEORETICAL MODEL; TUBERCULOSIS, PULMONARY; ULTRASTRUCTURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COLONY COUNT, MICROBIAL; DRUG MONITORING; FEMALE; HUMANS; LIPID DROPLETS; MALAWI; MALE; MIDDLE AGED; MODELS, THEORETICAL; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84948709583     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ195     Document Type: Article

References (43)

1. Global Alliance for Tuberculosis Drug Development. Tuberculosis: scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb) 2001; 81(Suppl 1): 1-52.
2. Salomon JA, Lloyd-Smith JO, Getz WM, et al. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med 2006; 3: e273.
3. World Health Organization. Global tuberculosis report 2014. Geneva, Switzerland: WHO, 2014.
4. Sloan DJ, Davies GR, Khoo SH. Recent advances in tuberculosis: new drugs and treatment regimens. Curr Respir Med Rev 2013; 9: 200-10.
5. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013; 12: 388-404.
6. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacinbased regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371: 1577-87.
7. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014; 371: 1599-608.
8. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014; 371: 1588-98.
9. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373: 1183-9.
10. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-8.
11. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-80.
12. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-38.
13. Mitchison DA. The search for new sterilizing anti-tuberculosis drugs. Front Biosci 2004; 9: 1059-72.
14. Zhang Y, YewWW, Barer MR. Targeting persisters for tuberculosis control. Antimicrob Agents Chemother 2012; 56: 2223-30.
15. Phillips PP, Fielding K, Nunn AJ. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One 2013; 8: e63840.
16. Davies GR, Brindle R, Khoo SH, Aarons LJ. Use of nonlinear mixedeffects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob Agents Chemother 2006; 50: 3154-6.
17. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-25.
18. Sloan DJ, Corbett EL, Butterworth AE, et al. Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings. J Clin Microbiol 2012; 50: 2315-20.
19. Carroll NM, Uys P, Hesseling A, et al. Prediction of delayed treatment response in pulmonary tuberculosis: use of time to positivity values of Bactec cultures. Tuberculosis (Edinb) 2008; 88: 624-30.
20. Weiner M, Prihoda TJ, BurmanW, et al. Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol 2010; 48: 4370-6.
21. Daniel J, Maamar H, Deb C, Sirakova TD, Kolattukudy PE. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog 2011; 7: e1002093.
22. Deb C, Lee CM, Dubey VS, et al. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One 2009; 4: e6077.
23. Garton NJ, Waddell SJ, Sherratt AL, et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 2008; 5: e75.
24. Kremer L, de Chastellier C, Dobson G, et al. Identification and structural characterization of an unusual mycobacterial monomeromycolyldiacylglycerol. Mol Microbiol 2005; 57: 1113-26.
25. International Union Against Tuberculosis and Lung Disease. Laboratory diagnosis of tuberculosis by sputum microscopy. Available at: http://www.theunion.org/what-we-do/publications/technical/laboratorydiagnosis-of-tuberculosis-by-sputum-microscopy-the-handbook. Accessed 18 March 2015.
26. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
27. Ministry of Health Malawi. National TB Control Programme manual. 6th ed. Lilongwe: Ministry of Health Malawi, 2007.
28. Ministry of Health Malawi. Guidelines for the use of antiretroviral therapy in Malawi. 3rd ed. Lilongwe: Ministry of Health Malawi, 2008.
29. Ministry of Health Malawi. Clinical management of TB in children and adults. 1st ed. Lilongwe: Ministry of Health Malawi, 2011.
30. Ralph AP, Ardian M, Wiguna A, et al. A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax 2010; 65: 863-9.
31. Davies GR, Khoo SH, Aarons LJ. Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. J Antimicrob Chemother 2006; 58: 594-600.
32. Garton NJ, Christensen H, Minnikin DE, Adegbola RA, Barer MR. Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology 2002; 148(pt 10): 2951-8.
33. Greenspan P, Fowler SD. Spectrofluorometric studies of the lipid probe, nilered. J Lipid Res 1985; 26: 781-9.
34. Lamprecht A, Benoit JP. Simple liquid-chromatographic method for Nile Red quantification in cell culture in spite of photobleaching. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 787: 415-9.
35. R Core Team. R: A language and environment for statistical computing. Available at: http://www.R-project.org/. Accessed 18 March 2015.
36. Crampin AC, Mwaungulu JN, Mwaungulu FD, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 2010; 24: 417-26.
37. Marx FM, Dunbar R, Enarson DA, et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis 2014; 58: 1676-83.
38. Fedorov V, Mannino F, Zhang R. Consequences of dichotomization. Pharm Stat 2009; 8: 50-61.
39. Davies GR, Cheirakul N, Saguenwong N, et al. A factorial study of the effect of HIV, tuberculosis and pharmacogenetics on the pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs. In: Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2008.
40. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-405.
41. Mac Kenzie WR, Heilig CM, Bozeman L, et al. Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One 2011; 6: e18358.
42. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med 2010; 181: 174-80.
43. Khomenko AG. The variability of Mycobacterium tuberculosis in patients with cavitary pulmonary tuberculosis in the course of chemotherapy. Tubercle 1987; 68: 243-53.